BR1400-1

DRUG2 trials

Sponsors

Boryung Pharmaceutical Co., Ltd

Conditions

Essential Hypertension

Phase 1

A Study to Evaluate the Pharmacokinetic, Pharmacodynamic Characteristics and the Safety After Administration by Doses of BR1400-1, BR1400-2, BR1400-3 in Healthy Adult Volunteers

CompletedNCT06889064

Boryung Pharmaceutical Co., LtdEssential Hypertension

Start: 2024-09-24End: 2024-10-08Updated: 2025-03-21

Phase 2

A Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension

Not yet recruitingNCT07373613

Boryung Pharmaceutical Co., LtdEssential Hypertension

Start: 2026-03-01End: 2027-02-01Target: 330Updated: 2026-01-28